Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
To read the full story
Related Article
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Moderna COVID-19 Booster to Start from December 17
December 17, 2021
- Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
- Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
- Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
- Shorter Booster Interval for All Citizens Difficult: Health Minister
December 8, 2021
- Health Minister Stresses Basic 8-Month Interval for Booster Shot
November 17, 2021
- Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
- Japan Approves Pfizer COVID-19 Vaccine for Booster Use
November 11, 2021
- Pfizer’s COVID-19 Booster Now in Line for Approval for Age 18-Plus
November 11, 2021
- Booster Shots to Start with Pfizer Vaccine: MHLW
November 2, 2021
- Japan Panel OKs Booster Shots for All People Who Took 2 Doses
October 29, 2021
- Govt to Deliver 4.12 Million Comirnaty Doses for COVID-19 Boosters: Minister
October 19, 2021
- Japan Clinches Deal for 120 Million Extra Pfizer Vaccine Doses
October 8, 2021
- MHLW Eyes Booster Shots for Healthcare Workers from December
September 24, 2021
- Japan Needs Setups to Execute Booster Shots by Year-End: Minister
September 22, 2021
- Japan to Offer COVID-19 Booster Shots, Targets to Be Discussed Later
September 21, 2021
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- Japan in Talks with Pfizer over 120 Billion Booster Shots for 2022
August 23, 2021
- Japan Secures Enough Doses for Booster Shots Next Year: Minister
August 18, 2021
REGULATORY
- MHLW Project Team Compiles Interim Proposal for Supporting Healthcare Startups
April 30, 2024
- Govt’s Healthcare Advisors Call for Bolstering AMED Staff: 2025-2029 Strategy
April 30, 2024
- Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
- MHLW’s Generic Industry Panel to Call for 5-Year Intensive Reform Period
April 26, 2024
- Jaypirca, Prevymis, Relvar and More on MHLW Panel Agenda for May 9
April 26, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…